Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 39

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 39
---
 Alpine Rewards and the individual compensation advisors employed by Alpine Rewards does not create any conflict of interest pursuant to the SEC rules and the Nasdaq listing rules.

#### Use of Competitive Market Compensation Data
The Compensation Committee believes that it is important when making its compensation decisions to be informed as to the current practices of comparable public companies with which we compete for top talent. To this end, the Compensation Committee directed Alpine Rewards to develop a proposed list of our peer group companies to be used in connection with assessing the compensation practices of the publicly traded companies with whom we compete.

#### Mirum Pharmaceuticals2025 Proxy Statement33

#### TABLE OF CONTENTS

#### Executive Compensation
In August 2023, Alpine Rewards proposed, and the Compensation Committee approved, a group of companies that would be appropriate peers to be utilized with respect to compensation decisions based on the following criteria:

• Industry Sector and Stage – Commercial companies with a focus on rare disease and/or similar therapeutic focus

• Market Capitalization – Range of $300 million to $3.0 billion

#### •

#### Revenue

#### – Range of $100 million to $400 million
#### •

#### Location

#### – Biotechnology hub markets
At the time we selected our peer group, we were approximately the 50 th percentile of the peer group in terms of the key metrics listed above. The peer group utilized with respect to 2024 compensation decisions was as follows:

| Acadia Pharmaceuticals    |     | Deciphera Pharmaceuticals  |
| Agios Pharmaceuticals     |     | Evolus                     |
| Amicus Therapeutics       |     | Intercept Pharmaceuticals  |
| Amylyx Pharmaceuticals    |     | Ironwood Pharmaceuticals   |
| Ardelyx                   |     | MannKind                   |
| BioCryst Pharmaceuticals  |     | Rhythm Pharmaceuticals     |
| Catalyst Pharmaceuticals  |     | Syndax Pharmaceuticals     |
| Collegium Pharmaceuticals |     | Travere Therapeutics       |
| CymaBay Therapeutics      |     | Ultragenyx Pharmaceuticals |
| Cytokinetics              |     | Vericel                    |

Using data compiled from the peer companies, or peer data, Alpine Rewards completed an assessment of our executive compensation to inform the Compensation Committee’s determinations regarding executive compensation for 2024. Alpine Rewards prepared and the Compensation Committee reviewed, a range of market data reference points (generally at the 25 th , 50 th , and 75 th percentiles of the market data) with respect to base salary, performance bonuses, equity compensation (valued based on